Parexel and Palantir to accelerate clinical data delivery and power clinical outcomes for patients
Parexel will leverage Palantir’s Foundry and Artificial Intelligence Platform to further power its clinical data platform
Parexel will leverage Palantir’s Foundry and Artificial Intelligence Platform to further power its clinical data platform
Keimed is a leading wholesale pharma distribution with industry leading operating metrics
Open a printable version of this pageEmail the URL of this page to a friend
ALPHA Phase III trial showed first-in-class, oral, Factor D inhibitor as add-on to Ultomiris or Soliris improved haemoglobin levels and reduced anaemia and fatigue
NULIBRY is a first-in-class synthetic cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A
Commercial terms include research funding and milestones and/or royalty payments to Evotec based on the success of the program
The newly issued patent, US Patent No. 11,957,647, provides both expanded scope of protection as well as longer patent term
Breakthrough Therapy designation for pain associated with DPN granted by FDA
Thermo Fisher has equipped this Centre for Innovation with state-of-the-art platforms such as CellInsight CX7 LZR Pro High Content Screening Platform
Biocon will undertake the development, manufacturing and supply of the drug product, and Biomm will be responsible for obtaining regulatory approval and commercialization in the Brazilian market
Subscribe To Our Newsletter & Stay Updated